Background: Liquid embolic agents are the preferred embolic material in endovascular treatment of pial and brain arteriovenous malformations and dural arteriovenous fistulas (DAVFs). There is little choice available in interventional neuroradiology practice other than two of the most commonly used liquid embolic agents-n-butyl cyanoacrylate and the Onyx liquid embolic system (ev3 Neurovascular, Irvine, California, USA). PHIL (Precipitating Hydrophobic Injectable Liquid) (Microvention, Inc California, USA) is a new liquid embolic agent, CE marked and available for clinical use in Europe.
Objective: To present our preliminary experience using PHIL in treating cranial and spinal DAVFs.
Methods: Between September 2014 and January 2015, eight patients, with five cranial DAVFs and three spinal DAVFs were treated with PHIL as the sole embolic agent used with intent to cure. Clinical presentation, location of DAVF, Borden type, fluoroscopic time, radiation dose, procedural time, injecting microcatheter used, volume of PHIL injected, complications, immediate angiographic data, premorbid and discharge modified Rankin Scale score, and any neurologic deficits were included in the analysis.
Results: Seven patients were successfully treated with complete angiographic exclusion of the fistula in a single sitting. Treatment failed in one patient where only suboptimal microcatheter positioning could be achieved and PHIL failed to penetrate the fistula's nidus. Venous penetration was achieved in all other patients except one with a small fistula, but with adequate fistula penetration by the embolic material. No other technical complication or neurologic deterioration occurred in any of the patients.
Conclusions: PHIL liquid embolic agent appears to be an excellent alternative embolic material with certain advantages compared with other available liquid embolic agents. Further studies are required to fully evaluate its safety and efficacy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/neurintsurg-2015-011684 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Single PEdicle Embolization of Distal Middle Meningeal Artery using n-BCA (SPEED-n technique).
J Neurointerv Surg
January 2025
Semmes-Murphey Neurologic and Spine Institute, Memphis, Tennessee, USA
The Single Pedicle Embolization of the Distal Middle Meningeal Artery using n-butyl cyanoacrylate (n-BCA) (SPEED-n technique) offers an innovative approach to treating chronic subdural hematomas by targeting the pathological subdural membranes with precise and efficient embolization.1 2 3 This technical video demonstrates the SPEED-n technique, which employs a single catheter and dilute n-BCA (15-20%) to achieve distal penetration of the middle meningeal artery (MMA) network while minimizing procedure time and risks (video 1).neurintsurg;jnis-2024-022751v1/V1F1V1Video 1-Key features include a stepwise embolization strategy, leveraging inherent MMA anastomoses to ensure comprehensive vascular coverage and reduced non-target embolization.
View Article and Find Full Text PDFRetrograde thrombosis of the superficial sylvian vein following liquid adhesive hemostat use during craniotomy: illustrative case.
J Neurosurg Case Lessons
January 2025
Department of Neurosurgery, University of California, Irvine, Orange, California.
Background: Intravascular injection of liquid adhesive hemostats is a rare but serious complication that can result in cerebral thromboembolism.
Observations: A 64-year-old female underwent orbitozygomatic craniotomy for posterior communicating artery aneurysm clipping with the routine use of a flowable hemostatic agent during extradural dissection. After placement of the aneurysm clip, flow was confirmed through the parent vessel and nearby branches.
Pre-surgical Embolization of Meningiomas: Analysis of Safety and Efficacy in a Mexican National Center And Proposal for a Classification of Preoperative Embolization of Meningiomas Based on Embolic Agent Penetration.
World Neurosurg
January 2025
Neurosurgical Fellow, Stroke Team México, American Association of Neurological Surgeons Student Chapter, Universidad Autónoma del Estado de Hidalgo, Hidalgo, 42160, México.
Introduction: Meningiomas are the most common primary central nervous system tumors, often requiring surgical resection. Presurgical embolization (PSE) is used to reduce intraoperative bleeding, although its effectiveness varies. This study evaluates the safety and efficacy of PSE using ethyl-vinyl alcohol (EVOH) in meningioma surgeries.
View Article and Find Full Text PDFSafety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial.
Lancet Microbe
December 2024
Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, Germany; German Center for Infection Research, Munich Partner Site, Munich, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology, Infection, and Pandemic Research, Munich, Germany; Unit Global Health, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany. Electronic address:
Background: The broad use of bedaquiline and pretomanid as the mainstay of new regimens to combat tuberculosis is a risk due to increasing bedaquiline resistance. We aimed to assess the safety, bactericidal activity, and pharmacokinetics of BTZ-043, a first-in-class DprE1 inhibitor with strong bactericidal activity in murine models.
Methods: This open-label, dose-expansion, randomised, controlled, phase 1b/2a trial was conducted in two specialised tuberculosis sites in Cape Town, South Africa.
Efficacy and safety of the PHIL embolic agent in the treatment of intracranial dural arteriovenous fistulas: results of the PHIL-dAVF study.
J Neurointerv Surg
January 2025
Diagnostic and Therapeutic Neuroradiology, Hôpital Purpan, Toulouse, France.
Background And Purpose: Embolization is the first-line treatment for dural arteriovenous fistulas (dAVF). The precipitating hydrophobic injectable liquid (PHIL) embolic agent is a non-adhesive copolymer with specific features and endovascular behavior. This study assessed its safety and efficacy in a prospective real-life cohort.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!